Loading clinical trials...
Loading clinical trials...
Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients With Leptomeningeal Metastases
Conditions
Interventions
Tucatinib Oral Tablet
Capecitabine tablets
+1 more
Locations
11
France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Georges-François Leclerc
Dijon, France
Centre Léon Bérard
Lyon, France
Institut régional du Cancer de Montpellier
Montpellier, France
Start Date
December 18, 2023
Primary Completion Date
December 1, 2026
Completion Date
June 1, 2027
Last Updated
November 18, 2025
NCT02422641
NCT06625775
NCT07476781
NCT04588545
NCT05809752
NCT06230055
Lead Sponsor
UNICANCER
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions